Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. - Wikidata - wikimedia - TriplyDB

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

http://www.wikidata.org/entity/Q33423563

about

Current understanding of interactions between nanoparticles and the immune system Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Anti-HIV-1 nanotherapeutics: promises and challenges for the future Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials Activation of latent HIV using drug-loaded nanoparticles Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1 Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Implementation challenges for long-acting antivirals as treatment.A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.HIV-1 neuroimmunity in the era of antiretroviral therapy.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery.The clinical role and cost-effectiveness of long-acting antiretroviral therapy Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.Nanotechnology and the treatment of HIV infection.pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission Long-acting slow effective release antiretroviral therapy.Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Next-generation oral preexposure prophylaxis: beyond tenofovir Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Long-acting injectable antiretrovirals for HIV treatment and prevention NanoART, neuroAIDS and CNS drug delivery.Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.A mini review of nanosuspensions development.Recent advancements in mechanical reduction methods: particulate systems.

P2860

Q26345204-C2F60F4C-1E44-42AD-B77F-E96DC1F4EAC9 Q26746912-E4F4E5DE-D569-405E-B2EB-075ACBB83026 Q26828464-A2552885-5C25-48BF-8500-4FEA466DF85A Q27318354-95E26733-81F5-4BFF-8976-0E589B37AC5B Q28087336-8CD0319E-34D7-49E5-8A83-C44ADAC6F0E0 Q28477657-0AF2D8D3-C77F-48F4-9BB5-A756B1FED9E6 Q28728527-B86AA920-15EF-461B-A3A3-4897E5FBE8F4 Q30372133-A78FFD55-1E91-49EE-8741-AAD094E380F8 Q30375397-C0F59478-A49E-4BF4-9384-8E491181FDB1 Q30431343-7B314CC3-2A27-48DA-AEF3-E002DBEFD633 Q30493643-013D2065-0F05-49CF-93F4-AA7F71D03C56 Q33517859-4EDDDA22-8B6C-4AC2-97CA-301CD67D975F Q33642023-75F5EB6B-0B8D-4D91-B550-7844E47DA75B Q33733529-E6F9C28E-624B-4757-9B59-1B661CF03AA0 Q33819656-DC0406CF-94BA-4DDC-B10C-8EDB91E3826D Q33826308-2C82D51C-8FF7-4D4F-B68B-64E5D3F9D159 Q33873990-C30E538C-0501-4695-904B-4741388CDC0F Q34102246-70DDD0B0-DEE5-48BD-BBD1-D86C874521C4 Q34571360-D38D9697-56AA-441D-AAF7-F08921F600F7 Q34728884-44869DB0-A705-4974-9DB6-9B834A17B3F4 Q35071617-E24758CA-CD17-4E97-BBD2-FE036CACF7DE Q35179026-C7BE8556-63DD-4872-AF8C-42431146FEB2 Q35197271-36D205B9-2416-4E66-919A-D6259A70974E Q35314702-52AC5938-9062-4230-BD80-6D83488FA444 Q35557326-74402739-EF7E-4236-9AAF-DB99F9CD169E Q35943647-49EE8EE3-0941-4B48-AD5B-A43E470D578C Q36032459-DAA74DE2-9A01-485C-AEEB-CB109743915D Q36262152-EAC5DC08-BD2C-4823-B751-43C570CAD485 Q36888077-CC27045B-F295-4E8A-960F-5BFADFA966B2 Q36901505-0ECEEFC1-8F05-47AB-AD3C-EDA773412EF3 Q37067126-D51912BE-FAE2-4ECF-A17E-F8E440529F9E Q37263531-F02F392F-6E42-4CA2-8C6B-14E63175F7D2 Q37263885-2CAC07E5-415D-4A89-92CE-9241EF723677 Q37272776-C005BEFF-AE9C-44C0-AD76-76CC82EB3981 Q37538776-7F4D2E53-22B3-4018-86F6-2FBB5DC60A16 Q37637073-2BC72AD1-C422-43E2-B580-132F690DD72B Q37692595-2A221A09-C3E2-4830-BCCE-4215911FD388 Q37704651-FD61538C-7047-4FEF-9A57-BAE5A1A1F228 Q37970772-D370B641-C40C-44DA-837E-0E83C1866AA3 Q38132471-375DA767-6134-4A7E-A27C-D3593318B016

P2860

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

http://www.wikidata.org/entity/Q33423563

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@ast

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@en

type

label

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@ast

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@en

prefLabel

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@ast

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@en

P1433

Q33423563-D497432D-05B9-4510-A1A3-1E316C41F664

P1476

Q33423563-C58E71E3-22A0-4EF9-B8AC-8CD75597991B

P2093

Q33423563-24FA7481-141D-4E31-B571-EBFCE24FF5C6

Q33423563-505CF7A9-E62B-4E9C-8167-4B9629FAA2B6

Q33423563-5A825ED0-C459-47C2-A080-413923957B6D

Q33423563-6841CC93-921B-4483-9E6C-0ABA593AB833

Q33423563-6DCF7D9A-0D40-4C1F-9010-80655A7F80DB

Q33423563-7B126166-30EE-40B8-927A-C5E6CD36C12A

Q33423563-7B58DBBB-9449-4373-849B-558C4DF67D57

Q33423563-7C831AB1-BFB4-4B51-91C5-3B1D52A2B6FA

Q33423563-A336BE95-2561-4304-89DF-CF8F58DD6874

Q33423563-AF8959C3-BC9A-454B-800F-98615A6E297C

P304

Q33423563-93C48AB6-C147-456A-A457-6E475664FE79

P31

Q33423563-EEED9770-0E93-46B5-A58E-A3E5C6F72728

P356

Q33423563-8140DFD9-0576-4FEA-AECA-12FC2F3A60FE

P407

Q33423563-F61F9D98-833A-47BC-95DD-E5041C31FB98

P433

Q33423563-F6290287-A97B-486A-AC11-E1525BA268F9

P478

Q33423563-D5FD29CF-E27F-477B-95CA-DD13FC374627

P577

Q33423563-A3830513-1CB5-4800-A48C-5E79C9CC3AF5

P5875

Q33423563-3437A122-A41E-44AA-B4C6-7A2B345E521B

P698

Q33423563-367D5EB1-32F8-425A-BCC2-4FE8636C7B23

P921

Q33423563-073A0D8C-C389-4994-AC1F-79C84656C550

Q33423563-4798EFC7-8DD0-47F4-BC37-84572C33D029

P356

J.EJPB.2009.03.006

P1433

European Journal of Pharmaceutics and Biopharmaceutics

P1476

Development of a long-acting i ...... ne (TMC278) for HIV treatment.

@en

P2093

Alfons Wouters

http://www.w3.org/2001/XMLSchema#string

Esther Basstanie

http://www.w3.org/2001/XMLSchema#string

Fred Stappers

http://www.w3.org/2001/XMLSchema#string

Gerben van 't Klooster

http://www.w3.org/2001/XMLSchema#string

Guenter Kraus

http://www.w3.org/2001/XMLSchema#string

Jan Rosier

http://www.w3.org/2001/XMLSchema#string

Koen Iterbeke

http://www.w3.org/2001/XMLSchema#string

Laurent Schueller

http://www.w3.org/2001/XMLSchema#string

Lieven Baert

http://www.w3.org/2001/XMLSchema#string

Marc François

http://www.w3.org/2001/XMLSchema#string

P304

502-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPB.2009.03.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24241364

http://www.w3.org/2001/XMLSchema#string

P698

19328850

http://www.w3.org/2001/XMLSchema#string

P921